Literature DB >> 22978638

Dysplastic-reactive choroid plexus presenting as an intramedullary tumor of the cervicomedullary junction in a patient with myelomeningocele.

Amit Singla1, V Michelle Silvera, Pedro Ciarlini, Benjamin C Warf.   

Abstract

Dysplastic structural lesions within the fourth ventricle have been reported in patients with Chiari malformation type II (CM-II). The authors report the unique case of a 22-year-old patient with myelomeningocele who presented with progressive pain, decreasing hand function, and lower cranial nerve dysfunction in the context of a slowly enlarging intramedullary mass at the cervicomedullary junction. At surgery a multinodular mass attached to caudally displaced fourth ventricle choroid plexus was completely removed from an expanded central canal. The histopathological findings were consistent with dysplastic-reactive choroid plexus. Postoperatively the patient experienced relief of pain and improvement in hand strength. To the authors' knowledge, this is the first reported case in which dysplastic fourth ventricle choroid plexus was displaced caudally through the obex to become an intramedullary lesion at the cervicomedullary junction. Its subsequent slow enlargement with progressive neurological deficits may have been secondary to reactive inflammatory changes. For patients with myelomeningocele and CM-II, intramedullary dysplastic-reactive choroid plexus should be included in the differential diagnosis of mass lesions in this location.

Entities:  

Mesh:

Year:  2012        PMID: 22978638     DOI: 10.3171/2012.8.PEDS12262

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  1 in total

Review 1.  Enhancing nodular lesions in Chiari II malformations in the setting of persistent hindbrain herniation: case report and literature review.

Authors:  Alexa Semonche; Ashish H Shah; Daniel G Eichberg; Sakir H Gultekin; Ricardo J Komotar; Michael E Ivan
Journal:  Childs Nerv Syst       Date:  2019-05-07       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.